BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 28/07/2026

FDA Amends Fee Rate for Using Priority Review Voucher in Fiscal Year 2026

The FDA is updating a notice to reflect changes made by Congress in February 2026, which require sponsors of human drug applications using rare pediatric disease priority review vouchers to submit a priority review user fee upon application submission.

Source: Federal Register — Health and Human ServicesOpen original release →